02May 2017 by Bianca Ozcan No Comments

First treatment licensed for primary progressive MS in the US

Research News
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US. It is the first licensed treatment for people with primary progressive MS. The decision was made by the US Food and Drug Administration (FDA). In its latest trial results, researchers found that ocrelizumab reduced relapses, MRI activity and slowed progression in relapsing MS. It was also found to slow progression in primary progressive MS. It’s currently being reviewed by the European Medicines Agency (EMA), the body responsible for drug licensing in Europe. A decision is expected later this year. - See more here
Read More
02May 2017 by Bianca Ozcan No Comments
French Conference

French Conference

Research News
Top neurologists from the world of science and medicine showcased developments in MS research at the 26th annual conference of French MS organisation ARSEP this month. 700 participants were treated to a range of workshops and presentations on such wide-ranging subjects as myelin reparation, the role of MRI in diagnosing and treating MS, and art therapy, all broadcast to a live online audience of 1000 viewers. Research highlights included a presentation from Dr Bruno Stankoff on the potential for innovative imagery techniques to improve myelin reparation, as well as a session from Professor David Laplaud on the impact of lymphocytes on the immune system among people with MS. Attendees also enjoyed workshops around such thought-provoking themes as the helpers and the helped, art therapy, and therapeutic education See more here
Read More